TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01864434

Intervention type: DEVICE
Intervention: Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)
Description: The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.

Intervention type: DEVICE
Intervention: Zimmer PCR TKA
Description: The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
Study: NCT01478984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-Stage group
Description: Patients randomized to One-Stage group were completely revascularizated in one time PCI,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Staged group
Description: patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
Study: NCT02230345

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Description: Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acidified milk
Description: Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
Study: NCT01255280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)
Description: This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information, Motivation, Behavioral skills change approach to sexual risk reduction
Description: The comparison condition will only receive the two IMB risk reduction sessions.
Study: NCT01164007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle.
Study: NCT04225858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of sentinel lymph node biopsy
Description: No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
Study: NCT02927444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP606
Description: A single intramuscular injection into the thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: A single intramuscular injection into the thigh
Study: NCT03737552

Intervention type: OTHER
Intervention: Polysomnography
Description: Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).

Intervention type: OTHER
Intervention: Polysomnography
Description: Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).
Study: NCT01362101

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)
Description: 60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~* Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~* Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)
Description: 60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~* Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~* Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol.
Study: NCT01818687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan
Description: body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
Study: NCT00551083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Decision Support System for Depression (CDSS-D)
Description: The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR\*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would.
Study: NCT02999607

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 0.5 mA, 1mA, 2mA for 10 minutes each

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 0.5 mA, 1mA, 2mA for 10 minutes each
Study: NCT01794910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle therapy
Description: The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
Study: NCT02972710

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine thoracic spine thrust manipulation
Description: The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seated thoracic spine thrust manipulation
Description: The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
Study: NCT03039387

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal transcranial direct current stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation (sham)
Description: for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
Study: NCT00477815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: greater than or equal to 2 x 106 CD34+/kg by IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: 500 mcg by Subcutaneous QD

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90Y-Zevalin
Description: Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111In Zevalin
Description: 5.0 mCi by IV
Study: NCT02800733

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saffron
Description: 20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 20 patients with mild to moderate GAD who receive sertraline will receive placebo too
Study: NCT04037228

Intervention type: DEVICE
Intervention: KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)
Description: The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
Study: NCT04086355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oromotor exercises and neuromuscular electrical stimulations
Description: treatment study group with occupational exercises and electrical stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oromotor exercises and neuromuscular electrical stimulations
Description: treatment study group with occupational exercises and electrical stimulation
Study: NCT03461939

Intervention type: OTHER
Intervention: ePRIME symptom monitoring tool
Description: ePRIME is an online system for patients to self-report symptoms and AE during cancer treatment. ePRIME allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating notifications for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
Study: NCT03264144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norms campaign
Description: Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
Study: NCT06043336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, granisetron & palonosetron
Description: . Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, granisetron & palonosetron
Description: . Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
Study: NCT02448199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam and Glucosamine
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine
Description: Active Comparator
Study: NCT00181844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine
Description: Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children \<12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
Study: NCT03790644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exoskeleton assist
Description: A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community.
Study: NCT01605669

Intervention type: OTHER
Intervention: Tranthoracic Echocardiogram
Description: standard measurement

Intervention type: DEVICE
Intervention: Cardiac Ascultation Recordings with Electronic stethoscope
Description: 3M device
Study: NCT00678730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta 9 tetrahydrocannabinol
Description: 0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: delta 9 tetrahydrocannabinol
Description: 0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
Study: NCT01610297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670
Description: Oral dose of ICL670 at 10 mg/kg daily
Study: NCT04502901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX0826
Description: investigational AR antagonist
Study: NCT02453009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02507154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + NK cells
Study: NCT01554098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strategy : Supine first
Description: The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strategy : dynamic first
Description: The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
Study: NCT02453009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Pharmaceutical form : soft gelatin capsules Route of administration: oral
Study: NCT00631852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American Ginseng root
Description: four, 250mg tablets daily 5-14 days prior to surgery
Study: NCT00833352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D Therapy
Description: Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-D Therapy
Description: Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
Study: NCT06125496

Intervention type: OTHER
Intervention: Pain management
Description: Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP

Intervention type: OTHER
Intervention: Pain management
Description: Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP
Study: NCT04502901

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of KX-826
Study: NCT02639910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: idelalisib dose: 150 mg twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: venetoclax dose: 400 mg once daily orally
Study: NCT00359242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Sleeping and Soothing
Description: Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Sleeping and Soothing
Description: Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated Food Exposure
Description: Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated Food Exposure
Description: Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
Study: NCT01825122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol
Study: NCT02648503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Using rocuronium and reversal with sugammadex
Study: NCT01825122

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01857765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Range of motion stretching exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Follow-up with surgeon's clinic
Study: NCT02648503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular block
Description: Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
Study: NCT01857765

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up
Description: Follow-up with surgeon's clinic
Study: NCT01869478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Thrombolysis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Arterial Reperfusion
Study: NCT03326674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel and Capecitabine
Description: Tesetaxel plus reduced dose of Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine alone at approved dose
Study: NCT00408564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT04221607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensate Focus exercise
Description: Structured exercise to enhance intimacy